Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

41.43
+0.03000.07%
Post-market: 41.430.00000.00%17:38 EST
Volume:605.48K
Turnover:25.21M
Market Cap:1.78B
PE:-11.87
High:42.38
Open:41.51
Low:40.77
Close:41.40
52wk High:45.46
52wk Low:13.37
Shares:42.88M
Float Shares:21.08M
Volume Ratio:1.03
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4892
EPS(LYR):-2.5506
ROE:-28.57%
ROA:-18.82%
PB:3.25
PE(LYR):-16.24

Loading ...

CFO Ryan Savitz Reports Disposal of Common Shares in Dianthus Therapeutics Inc

Reuters
·
Sep 12

Dianthus Therapeutics Inc. Files Final Prospectus for $270 Million Public Offering, Expanding Shareholder Opportunities

Reuters
·
Sep 11

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11

BRIEF-Dianthus Therapeutics Announces Pricing Of Upsized $251 Million Underwritten Public Offering

Reuters
·
Sep 10

BUZZ-Dianthus Therapeutics surges again ahead of planned equity raise

Reuters
·
Sep 10

Dianthus Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
Sep 09

Dianthus Therapeutics Inc. Announces $150 Million Underwritten Public Offering to Advance Antibody Therapeutics Development

Reuters
·
Sep 09

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

THOMSON REUTERS
·
Sep 09

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

Dow Jones
·
Sep 08

BUZZ-U.S. STOCKS ON THE MOVE-Sanofi SA, Nutanix, Bullish

Reuters
·
Sep 08

Dianthus Therapeutics Shares Reverse Course, Last up 19.3% After Mid-Stage Trial Data for Its Muscle-Weakening Drug

THOMSON REUTERS
·
Sep 08

Evercore ISI Adjusts Dianthus Therapeutics Price Target to $72 From $50, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Dianthus Therapeutics Shares Reverse Premarket Gains, Last Down 13.2%

THOMSON REUTERS
·
Sep 08

BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences

Reuters
·
Sep 08

BUZZ-Dianthus Therapeutics rises after mid-stage trial win for muscle-weakening drug

Reuters
·
Sep 08

Dianthus Therapeutics Inc - Claseprubart Shows Favorable Safety Profile

THOMSON REUTERS
·
Sep 08

Dianthus Therapeutics Inc - Phase 3 Gmg Trial for Claseprubart Anticipated to Start in 2026

THOMSON REUTERS
·
Sep 08

Dianthus Therapeutics Inc. Announces Phase 2 MaGic Trial Results for Claseprubart (DNTH103) in Generalized Myasthenia Gravis

Reuters
·
Sep 08

Dianthus Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 21

Wedbush Raises Price Target on Dianthus Therapeutics to $42 From $34, Keeps Outperform Rating

MT Newswires Live
·
Aug 21